BVNRY.US Bavarian Nordic A/S ADR

Healthcare Biotechnology USA Stocks
11.68 USD
Close of Nov 14, 2026
8.76 12.72
Market cap
USD 2.61B
P/E
11.6x
P/B
1.34x
ROE
11.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BVNRY.US undervalued?

Graham number
Price11.68
Graham value14.08
Discount17.1%

BVNRY.US trades 17.1% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bavarian Nordic A/S ADR fundamental analysis

No fundamental analysis for Bavarian Nordic A/S ADR yet.

Bavarian Nordic A/S ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bavarian Nordic A/S ADR

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN …

Full company profile